Investment Centers of America Inc. lifted its stake in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 15.8% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 78,758 shares of the biopharmaceutical company’s stock after buying an additional 10,736 shares during the period. Investment Centers of America Inc.’s holdings in Bristol-Myers Squibb were worth $4,265,000 at the end of the most recent quarter.
Several other large investors also recently made changes to their positions in the stock. Blue Chip Partners Inc. lifted its holdings in Bristol-Myers Squibb by 0.8% during the first quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock worth $116,000 after acquiring an additional 17 shares during the period. Keel Point LLC raised its stake in shares of Bristol-Myers Squibb by 0.3% in the first quarter. Keel Point LLC now owns 6,286 shares of the biopharmaceutical company’s stock valued at $342,000 after buying an additional 18 shares during the period. Staley Capital Advisers Inc. raised its stake in shares of Bristol-Myers Squibb by 0.3% in the first quarter. Staley Capital Advisers Inc. now owns 6,962 shares of the biopharmaceutical company’s stock valued at $379,000 after buying an additional 24 shares during the period. Shayne & CO. LLC raised its stake in shares of Bristol-Myers Squibb by 0.7% in the first quarter. Shayne & CO. LLC now owns 4,017 shares of the biopharmaceutical company’s stock valued at $218,000 after buying an additional 27 shares during the period. Finally, Founders Capital Management LLC raised its stake in shares of Bristol-Myers Squibb by 0.7% in the first quarter. Founders Capital Management LLC now owns 4,097 shares of the biopharmaceutical company’s stock valued at $223,000 after buying an additional 29 shares during the period. 68.80% of the stock is currently owned by institutional investors.
Several analysts have issued reports on BMY shares. Jefferies Group LLC boosted their target price on Bristol-Myers Squibb from $66.00 to $72.00 and gave the company a “buy” rating in a research note on Monday, September 11th. Vetr upgraded Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $62.23 target price on the stock in a research note on Wednesday, July 12th. Hilliard Lyons lowered Bristol-Myers Squibb from a “long-term buy” rating to a “neutral” rating and set a $65.00 target price on the stock. in a research note on Tuesday, September 12th. Goldman Sachs Group, Inc. (The) reiterated a “buy” rating and set a $63.00 price objective on shares of Bristol-Myers Squibb in a research note on Wednesday, August 9th. Finally, BMO Capital Markets reiterated an “underperform” rating and set a $47.00 price objective (down from $51.00) on shares of Bristol-Myers Squibb in a research note on Wednesday, July 26th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $62.66.
Bristol-Myers Squibb Company (NYSE:BMY) traded down 0.33% during trading on Friday, hitting $62.48. The stock had a trading volume of 10,407,558 shares. The company has a 50-day moving average of $58.56 and a 200 day moving average of $55.95. The firm has a market cap of $102.46 billion, a P/E ratio of 22.82 and a beta of 1.18. Bristol-Myers Squibb Company has a 52-week low of $46.01 and a 52-week high of $63.47. Bristol-Myers Squibb also was the recipient of unusually large options trading activity on Thursday. Traders acquired 781 put options on the company. This is an increase of approximately 117% compared to the typical volume of 360 put options.
Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.73 by $0.01. Bristol-Myers Squibb had a net margin of 22.66% and a return on equity of 32.33%. The firm had revenue of $5.14 billion during the quarter, compared to analysts’ expectations of $5.09 billion. During the same quarter last year, the company posted $0.69 EPS. The firm’s quarterly revenue was up 5.6% on a year-over-year basis. On average, equities research analysts predict that Bristol-Myers Squibb Company will post $2.98 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, November 1st. Shareholders of record on Friday, October 6th will be given a $0.39 dividend. The ex-dividend date is Thursday, October 5th. This represents a $1.56 annualized dividend and a yield of 2.50%. Bristol-Myers Squibb’s dividend payout ratio is presently 56.73%.
ILLEGAL ACTIVITY NOTICE: “Investment Centers of America Inc. Raises Holdings in Bristol-Myers Squibb Company (BMY)” was originally posted by TrueBlueTribune and is owned by of TrueBlueTribune. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.truebluetribune.com/2017/09/17/investment-centers-of-america-inc-raises-stake-in-bristol-myers-squibb-company-bmy.html.
In other Bristol-Myers Squibb news, Director Theodore R. Samuels II purchased 6,000 shares of the firm’s stock in a transaction on Wednesday, August 2nd. The stock was bought at an average price of $55.94 per share, with a total value of $335,640.00. Following the transaction, the director now directly owns 18,000 shares of the company’s stock, valued at approximately $1,006,920. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Joseph C. Caldarella sold 9,340 shares of the firm’s stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total transaction of $560,400.00. Following the completion of the transaction, the senior vice president now directly owns 46,297 shares of the company’s stock, valued at approximately $2,777,820. The disclosure for this sale can be found here. Company insiders own 0.23% of the company’s stock.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.